Action GHDN BRAINSTORM CELL THERAPEUTICS INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Brainstorm Cell Therapeutics Inc. Deutsche Boerse AG

Actions

GHDN

US10501E2019

Temps Différé Deutsche Boerse AG
Autres places de cotation
 20:26:14 01/07/2024 		Varia. 5j. Varia. 1 janv.
0,3065 EUR -4,81% Graphique intraday de Brainstorm Cell Therapeutics Inc. -10,25% +33,26%
27/06 Brainstorm Cell Therapeutics fixe le prix d'un placement direct enregistré et d'un placement privé simultané MT
26/06 Brainstorm Cell Therapeutics Inc. S'aligne avec la Fda sur les aspects Cmc de l'essai clinique de phase 3B de Nurown® ? essai clinique de phase 3B CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program
Brainstorm Cell Therapeutics Prices Registered Direct Offering, Concurrent Private Placement
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn Clinical Trial
Brainstorm Cell Therapeutics Inc. Reaches Alignment with Fda on Cmc Aspects of Phase 3B Nurown®? Clinical Trial
Brainstorm Cell Therapeutics Announces Appointment of Haro Hartounian as EVP and COO
BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit from Longer-Term Treatment with NurOwn
Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024
Brainstorm Cell Therapeutics Inc. Announces Management Changes
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment for Phase 3b Trial in ALS
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
Brainstorm Cell Therapeutics Says FDA Agrees on Design of Phase 3B ALS Trial
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
BrainStorm Cell Therapeutics Inc. Announces Agreement with FDA on Special Protocol Assessment for Phase 3b Trial in ALS
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BCLI
  4. Action GHDN
  5. Actualités Brainstorm Cell Therapeutics Inc.
  6. Autres langues